Tempus AI, Inc. (TEM)
Should Investors Buy Tempus AI Stock Right Now?
Tempus AI (TEM -11.18%) is utilizing artificial intelligence to deliver better healthcare outcomes.
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
Tempus AI: Buying The Dip After 2025 Guidance Raise
Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying opportunity due to raised 2025 revenue guidance. The company, a leader in healthcare AI, focuses on revenue growth and customer adoption, with a proprietary data model for personalized healthcare treatment. Despite stock volatility, Tempus AI's 30% organic revenue growth and Ambry acquisition integration highlight its long-term potential in the healthcare AI market.
Tempus AI Is a Buy, If You Can Handle the Volatility
Tempus AI NASDAQ: TEM is an emerging AI player in the healthcare field with a robust outlook for long-term growth and profitability. The company uses AI to manage patient testing and help physicians generate timely diagnoses and treatment regimens.
Tempus AI Down 13%- Is It Time to Buy?
Shares of Nancy Pelosi's favorite artificial intelligence stock Tempus AI (NASDAQ:TEM) are falling more than 13% in morning trading after reporting fourth quarter and full-year 2024 earnings results yesterday after the market closed.
Nancy Pelosi’s Latest AI Stock Pick Tempus AI Is Up Big Today
Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash payments and $225 million in shares. Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM stock by buying 50 of the TEM January 2026 $20 call options. Tempus AI CFO Jim Rogers just sold over 31,000 shares, removing about $2.6 million of value from the stock. However, we wouldn’t read too much into the selling. Investors may want to use weakness as an opportunity. Last year we published our “The Next NVIDIA” report that called Palantir before its epic run. The free report comes with 38 pages of in-depth research on top AI stock ideas. However, it’s only available for a limited time. Click here to learn more and grab your complimentary copy. Plus, Nancy Pelosi took a stake in the TEM stock by buying 50 of the TEM January 2026 $20 call options in mid-January. Even Cathie Wood picked up about 600,000 shares across multiple funds last month. After a drop from a high of $91.45, last week the stock tumbled to $68 but has regained its composure and up 7% today so far today. Sparking the pullback, insiders have been selling. Tempus AI CFO Jim Rogers just sold over 31,000 shares, removing about $2.6 million of value from the stock. However, we wouldn’t read too much into the selling. For us, it’s not a significant cause for concern because the funds could be used for personal reasons. We also have to remember that Tempus AI is moving to revolutionize healthcare with artificial intelligence. Plus, the Ambry Genetics acquisition “complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies,” says CEO Eric Lefkofsky. The acquisition is also expected to strengthen Tempus AI’s product offerings and accelerate its road to positive free cash flow and profitability. Institutional Interest in Tempus is Still Strong At the end of 2024, Cathie Wood’s ARK Invest increased its stake in TEM by 132% by adding 3.14 million shares. Jane Street Group raised its stake by 443%. Ken Griffin’s Citadel Advisors picked up 131,800 shares. Dmitry Balyasny’s Balyasny Asset Management increased its stake by nearly 515%. Blackrock also picked up 445,900 shares. In addition, analysts at TD Cowen have a buy rating on the TEM stock with a $74 price target. TEM is also expected to present at TD Cowen’s 45th Annual Health Care Conference in early March. CFO Jim Rogers is expected to talk about TEM’s AI healthcare innovations and outlook. The post Nancy Pelosi’s Latest AI Stock Pick Tempus AI Is Up Big Today appeared first on 24/7 Wall St..
Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates
TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
Tempus AI Earnings: A Promising Business, But There Are Risks
Tempus AI's core business growth is slowing, raising doubts about its AI-led narrative and long-term sustainable growth rates. Despite impressive revenue growth projections, Tempus AI remains free cash flow negative, with concerns about its ability to convert EBITDA into free cash flow. The company's balance sheet is weak, with significant net debt and a potential need for additional capital in 2025.
Tempus AI, Inc. (TEM) Q4 2024 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Liz Krutoholow - Investor Relations Eric Lefkofsky - Founder & Chief Executive Officer Jim Rogers - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Mike Ryskin - Bank of America Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Doug Schenkel - Wolfe Research Andrew Brackmann - William Blair Mark Schappel - Loop Capital Dan Arias - Stifel David Westenberg - Piper Sandler Operator Thank you for standing by. My name is Jason, and I will be your conference operator for today.
EARNINGS ALERT: TEM
Tempus AI's (TEM) massive rally since its IPO last year took a step down with its latest earnings. The selling action after the company's miss is one George Tsilis attributes to a trend seen in small caps.
Tempus AI Gears Up For Q4 Earnings After 101% YTD Surge
Tempus AI Inc TEM will be reporting its fourth-quarter earnings on Monday. Wall Street expects a loss of 20 cents per share and $203.12 million in revenues as the company reports after market hours.
Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Recently, they've made some interesting moves like acquiring Ambry Genetics, launching the Olivia health app, and collaborating with IFLI. TEM also has other innovative assets like xT CDx, xH tests, and enhanced Tempus One that I think position it perfectly for agentic AI diagnostics.
